DK1333850T3 - Anvendelse af IL-13-inhibitorer til behandling af tumorer - Google Patents

Anvendelse af IL-13-inhibitorer til behandling af tumorer

Info

Publication number
DK1333850T3
DK1333850T3 DK01989341T DK01989341T DK1333850T3 DK 1333850 T3 DK1333850 T3 DK 1333850T3 DK 01989341 T DK01989341 T DK 01989341T DK 01989341 T DK01989341 T DK 01989341T DK 1333850 T3 DK1333850 T3 DK 1333850T3
Authority
DK
Denmark
Prior art keywords
subject
inhibitors
treat tumors
inhibitor
response
Prior art date
Application number
DK01989341T
Other languages
English (en)
Inventor
Jay A Berzofsky
Debra D Donaldson
Masaki Terabe
So Matsui
Nancy Noben-Trauth
William E Paul
Original Assignee
Genetics Inst
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26981351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1333850(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Us Gov Health & Human Serv filed Critical Genetics Inst
Application granted granted Critical
Publication of DK1333850T3 publication Critical patent/DK1333850T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DK01989341T 2000-10-20 2001-10-22 Anvendelse af IL-13-inhibitorer til behandling af tumorer DK1333850T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69360000A 2000-10-20 2000-10-20
US31818501P 2001-09-07 2001-09-07
PCT/US2001/051339 WO2002055100A2 (en) 2000-10-20 2001-10-22 Method and composition for inhibition of tumor growth and enhancing an immune response

Publications (1)

Publication Number Publication Date
DK1333850T3 true DK1333850T3 (da) 2008-12-01

Family

ID=26981351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01989341T DK1333850T3 (da) 2000-10-20 2001-10-22 Anvendelse af IL-13-inhibitorer til behandling af tumorer

Country Status (8)

Country Link
EP (2) EP2027867A1 (da)
JP (2) JP2004537500A (da)
AT (1) ATE405282T1 (da)
AU (1) AU2002243443A1 (da)
DE (1) DE60135481D1 (da)
DK (1) DK1333850T3 (da)
ES (1) ES2311558T3 (da)
WO (1) WO2002055100A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050069546A1 (en) * 2003-09-30 2005-03-31 Yaron Ilan Educated NKT cells and their uses in the treatment of immune-related disorders
CA2550651C (en) 2003-12-23 2018-01-23 Tanox, Inc. Novel anti-il 13 antibodies and uses thereof
EP1720573A4 (en) * 2004-02-27 2008-04-02 Centocor Inc METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
CN101111260B (zh) * 2005-02-04 2013-03-20 萨瓦克公司 存活蛋白肽疫苗
ES2817756T3 (es) 2006-09-08 2021-04-08 Abbvie Bahamas Ltd Proteínas de unión a interleuquina-13
AU2010269120B2 (en) * 2009-07-06 2015-09-24 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
MY188365A (en) 2010-12-16 2021-12-06 Genentech Inc Diagnosis and treatments relating to th2 inhibition
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013059630A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon.
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
BR112016004413A2 (pt) 2013-09-13 2017-10-17 Genentech Inc composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio
JP6029160B2 (ja) * 2014-02-21 2016-11-24 Ｉｄａｃセラノスティクス株式会社 固形がんの治療剤
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH07508179A (ja) * 1992-08-21 1995-09-14 シェリング・コーポレーション ヒトインターロイキン−１３
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
JPH09150569A (ja) 1995-11-29 1997-06-10 Riso Kagaku Corp 色画像形成用シート
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
BR9916209A (pt) * 1998-12-14 2001-12-26 Genetics Inst Cadeia de receptor de citocina
CN1230421C (zh) * 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
EP1268794A2 (en) * 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors

Also Published As

Publication number Publication date
WO2002055100A2 (en) 2002-07-18
EP1333850B1 (en) 2008-08-20
WO2002055100A3 (en) 2003-03-27
AU2002243443A8 (en) 2005-10-13
DE60135481D1 (de) 2008-10-02
EP2027867A1 (en) 2009-02-25
JP2004537500A (ja) 2004-12-16
JP2009046512A (ja) 2009-03-05
ES2311558T3 (es) 2009-02-16
ATE405282T1 (de) 2008-09-15
EP1333850A2 (en) 2003-08-13
AU2002243443A1 (en) 2002-07-24
WO2002055100A9 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
DK1333850T3 (da) Anvendelse af IL-13-inhibitorer til behandling af tumorer
ATE376434T1 (de) Injektionsgerät für mrna applikation
NZ524559A (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
DK1064027T3 (da) APO-2 Ligand-anti-her-2-antistofsynergier
EA200300348A1 (ru) Спирогетероциклические нитрилы, пригодные для применения в качестве обратимо действующих ингибиторов цистеиновых протеаз
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
DK1755659T3 (da) Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
DE60318826D1 (de) Alkoxypyridinderivate
DK1255845T3 (da) Modificerede cytokiner til anvendelse i cancerterapi
ATE317693T1 (de) Substituierte stilbene mit gefässschädigender aktivität
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
SE9904674D0 (sv) Novel compounds
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
WO2002067652A3 (en) Novel mutilple shoot proliferation and regeneration system for plants
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
ATE424217T1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
TR200200169T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60117783D1 (de) Naphthamidin-urokinasinhibitoren
NZ524560A (en) 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inibitors
NZ524561A (en) 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors